Expand All | Collapse All
Submit to JCP
We encourage you to submit your manuscript if it fits within the scope of The Journal of Clinical Psychiatry. Acceptance is contingent on favorable peer review. Our user-friendly electronic manuscript submission and peer-review system allows you to submit your manuscript online securely, conveniently, and instantly. The system will request that new authors register for an account; authors who have previously submitted should use their previous account login information. Authors can track the progress of their manuscripts from submission to final decision. Assistance is available via email if needed.
NOTE: This account is separate from your Psychiatrist.com and CMEInstitute.com accounts. Thus, even if you are already registered to access our sites, you will still need to establish an account in the manuscript submission system.
Founded in 1939, JCP is an international peer-reviewed journal that is published monthly. The JCP strives to publish academically sophisticated, methodologically sound manuscripts that are aimed more at the practicing clinical psychiatrist than the researcher.
Manuscripts should deal with the epidemiology, classification, and treatment of psychiatric disorders or development and validity of measurement instruments. Pertinent manuscript types include
Experimental drug trials involving a compound not currently available in the United States may be considered if (1) the compound is expected to be soon released in the United States or (2) it offers some unique and interesting clinical features.
To submit your concisely written, appropriately referenced, and focused manuscript that fits within this scope and the word count, see Manuscript Components.
The Journal of Clinical Psychiatry:
The Journal of Clinical Psychiatry is the official journal of the American Society of Clinical Psychopharmacology. The ASCP was founded in 1992, and its membership includes clinicians and researchers who study the use of pharmacology in clinical practice.
Include the following in the manuscript, prior to submission:
Include permissions from the source for the following:
At the time of manuscript submission or revision, the journal must have received a separate, completed Author Form from each individual author.
The Journal of Clinical Psychiatry (JCP): http://www.psychiatrist.com/documents/authorform.pdf
By signing the Author Form, the bylined author
By signing the Author Form, the corresponding author
This form can be submitted to the journal in 1 of 4 ways:
Persons listed as authors must have made contributions in each of these 4 areas:
All persons designated as authors should fulfill these 4 criteria, and all those who qualify should be listed as authors. All authors must have contributed sufficiently to the work to take public responsibility for the content. Acquisition of funding, collection of data, or general supervision of a research group, alone, does not justify authorship. If authorship is attributed to a group, each member must meet authorship criteria; group members who do not meet these criteria should be listed in an acknowledgment.
The corresponding author will serve on behalf of the other authors as the primary contact with the editorial office and is responsible for ensuring that the acknowledgment and direct support information are complete. This person is responsible for communicating with the other authors about revisions and final approval of the article.
Further detailed information can be found at the International Committee of Medical Journal Editors (ICMJE) website: http://www.icmje.org/.
Research for which results do not substantially overlap with previously published research by the same authors or group of authors qualifies as original research.
Manuscripts should be submitted to only 1 journal, which is to be held in confidence with that journal until review is complete, leading to rejection, revision, or acceptance by the journal or withdrawal by the authors. Poster presentations and submission to a clinical trials registry do not constitute previous publication, but notation should be made in the manuscript of any presentations and clinical trials registration.
For manuscripts that report analyses of preexisting data sets, provide details related to accessing the data set, including
This information should be inserted as a statement into the text’s Method, eg, “The original data set is available from...,” or any wording that's appropriate, or inserted at the end of the article (just before references), eg, “Additional information: The [full proper name of database] can be found at [specific URL].”
At end of end of the manuscript, just before references:
Additional information: The original data set for the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) is available from the National Institute on Alcohol Abuse and Alcoholism (http://www.niaaa.nih.gov).
Authors must obtain letters of permission to reproduce published material. These documents should be sent at the time of submission of the manuscript and can accompany the Author Form(s). The form(s) can be faxed to the Publications Manager at (901) 273–2752.
The journal requires the express transfer of copyright to Physicians Postgraduate Press, Inc., to protect the author(s) and Physicians Postgraduate Press, Inc., from misuse of copyrighted materials. All accepted manuscripts become the property of Physicians Postgraduate Press, Inc., and may not be published or posted online elsewhere, in part or in whole, without written permission from Physicians Postgraduate Press, Inc. [For authors who have received government funding from the NIH, see the section National Institutes of Health (NIH)–Funded Research Articles.] (See also Terms and Conditions.)
Physicians Postgraduate Press, Inc., publisher of The Journal of Clinical Psychiatry and The Primary Care Companion for CNS Disorders, must retain exclusive and unfettered copyright of published materials either in print or electronic formats in perpetuity. For those authors affiliated with institutions that carry open access policies: If, after peer review, you are invited by the editor to revise your manuscript, any author or coauthor affiliated with an institution that requires open access to published manuscripts must submit (1) a copy of the institution’s policy and (2) an acknowledgment from the institution that it has received an opt-out, waiver, or other official document signed by the author and the authorized designate from the institution. The opt-out, waiver, or other official document must represent the express direction of the author that the institution relinquishes any and all explicit or implicit rights of the institution to publish or house the manuscript in any form. The journal will permit the inclusion of metadata from the published article in open access repositories. Metadata include the following: published title, byline, citation, doi, abstract, funding information, and affiliations.
The publisher’s copyright protection lasts the life of the author plus an additional seventy (70) years. If a signed opt-out, waiver, or other official document is not obtained, the manuscript cannot be considered for publication by Physicians Postgraduate Press, Inc.
For authors of National Institutes of Health (NIH)–funded research articles, the requirement to opt out of open access policies for authors affiliated with the institutions that carry them is separate and apart from the obligation of authors of NIH-funded research articles who must adhere to the terms of NIH Public Access Policy. Authors of manuscripts accepted for publication in The Journal of Clinical Psychiatry or The Primary Care Companion for CNS Disorders that report original research funded in whole or in part by an NIH grant have the journal’s permission to submit their accepted manuscript to the National Library of Medicine’s PubMed Central in accordance with the NIH Public Access Policy provided that the manuscript is made publicly available no sooner than 6 months after the official date of print publication.
The World Health Organization (WHO) defines a clinical trial as “any research project that prospectively assigns human participants or groups of humans to 1 or more health-related interventions to evaluate the effects on health outcomes.”
The journal requires, as a condition of consideration for publication, registration of clinical trials in a public trials registry that meets the criteria noted in the following paragraphs. (Such registration does not constitute previous publication.)
Registration requirements are as follows:
A public trials registry must meet several criteria:
An acceptable registration must include, at minimum, the following:
For detailed information, please see "Frequently Asked Questions" of the ICMJE Recommendations (previously “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” website at http://www.icmje.org/about-icmje/faqs/clinical-trials-registration/.
The following trial registries meet the required criteria, although the journal does not advocate one particular registry:
Registry name, URL, and trial ID number must be provided in
At end of abstract:
Trial Registration: ClinicalTrials.gov identifier: NCT000123456
Trial Registration: Data used in this secondary analysis came from ClinicalTrials.gov identifier: NCT000123456
In Method section of article:
“The study was approved by the local ethics committee, written informed consent was obtained, and the study was registered at ClinicalTrials.gov (identifier: NCT000123456).”
If results of original research have been presented at a meeting or meetings, it does not constitute previous publication, and the manuscript may still be published for the first time with the journal. However, all information about presentations should be annotated in the manuscript.
In an endmatter footnote, include the following for each meeting:
Previous presentation: Poster presented at the ASCP annual meeting, Tampa, Florida, October 8–10, 2014.
Previous presentation: Presented at the 53rd Annual Meeting of the ACNP, Phoenix, Arizona, December 9, 2014; and the 28th ECNP Congress, Amsterdam, the Netherlands, August 30, 2014.
Authors are required to provide either (1) a statement indicating potential conflicts of interest involving their manuscript or (2) a statement that they have no potential conflicts. Conflicts should reflect activity by the author or his/her spouse within the last 36 months and include, but are not limited to
Potential conflicts of interest: Dr Smith serves on the advisory board of Anonymous and has served on the advisory boards of ABC Pharmaceuticals, DEF Research Group, and GHI; has received grant/research support from GHI; and has served on speakers bureau for Anonymous and XYZ. Dr Smith was an employee of ABC Pharmaceuticals at the time of this study but now works for Anonymous.
Potential conflicts of interest: None.
Potential conflicts of interest: The authors report no financial or other relationship relevant to the subject of this article.
Potential conflicts of interest: Dr Smith was an employee of ABC Pharmaceuticals at the time of this study but now works for Anonymous.
Potential conflicts of interest: Drs Smith and Jones are employees of ABC Pharmaceuticals.
Describe direct support in the manuscript; direct funding, support, sponsorship, or provision of materials includes salaries, equipment, supplies, etc, from organizations that may gain or lose financially through the publication of the manuscript.
Funding/support: This research was supported by grant XYZ from the National Institutes of Health and a small research grant to Dr Smith from the TUV Foundation. Materials for this study were supplied by ABC Pharmaceuticals.
If the study was directly supported in any manner, then a statement on the role of the sponsor in the study must be noted, including publication of the manuscript.
Role of the sponsors: The supporters had no role in the design, analysis, interpretation, or publication of this study.
Role of the sponsor: ABC Pharmaceuticals supplied materials and participated in formulating the outline of the study but had no role in study selection or interpretation of the evidence. Although staff at ABC reviewed the manuscript, final approval for the decision to submit the manuscript was the sole decision of the authors.
In accordance with the NIH Public Access Policy (http://publicaccess.nih.gov; update March 18, 2014), authors of manuscripts accepted for publication in ajournalthat report original research funded in whole or in part by a National Institutes of Health (NIH) grant must post their research in the NIH Manuscript Submission (NIHMS) System for later deposit in the National Library of Medicine’s PubMed Central (PMC):
Authors may include a footnote in the endmatter that acknowledges contributions of groups or persons who do not qualify for authorship. Acknowledged individuals might include those who have provided data gathering, writing, or clerical assistance; statistical or general review; or performance of special tests.
When specific individuals are acknowledged, 2 steps must be taken:
First: The Corresponding Author:
Second: The Manuscript must include the following information for each person named in the Acknowledgment:
Acknowledgments: The authors thank John M. Doe, PhD (XYZ Consulting, City, Country), supported by ABC Pharmaceuticals, for insights on methodology; and Michael T. M. Jones, MSc, for technical assistance and managing the subjects, and Ms Jane Smith, BA, for assistance with typing the manuscript, both from JKL University, City, State. Mr Jones and Ms Smith have no conflicts of interest to declare.
Unpublished material includes personal communications and unpublished data such as data on file and manuscripts in preparation, submitted but not yet accepted, or in press. Each type of unpublished material must meet a specific set of criteria for it to be included in the manuscript, but the most important criterion is that written permission from the source of the unpublished material must be submitted to the journal. See the Citations section under Manuscript Components for specifics on how to handle these types of citations.
Published by the International Committee of Medical Journal Editors (ICMJE), this document, formerly titled Uniform Requirements for Manuscripts Submitted to Biomedical Journals, covers ethical principles related to evaluating, improving, and publishing manuscripts, as well as technical aspects of preparing and submitting manuscripts.
The CONSORT Statement provides guidelines for improved reporting of clinical trials through the use of a checklist and study flow diagram.
The PRISMA Statement provides guidelines for transparent reporting of systematic reviews and meta-analyses through the use of a checklist and study flow diagram.
Manuscripts submitted for publication in the journal that meet its scope and submission criteria are sent to expert consultants for peer review. Please see Reviewers for details about the peer review process and information on becoming a reviewer.
Manuscripts accepted for publication after peer review will be copyedited for clarity, conciseness, and conformity with journal style and returned to the corresponding author for approval. Bylined authors are responsible for all statements in their work, including changes authorized by the corresponding author.
Articles are embargoed until they are published online at Psychiatrist.com. Contact JCPembargo@psychiatrist.com for information about a specific “In press” article for The Journal of Clinical Psychiatry. (See Copyright Policy and Terms and Conditions.)
The Journal of Clinical Psychiatry: The JCP offers authors of accepted articles and letters the opportunity to make their article or letter freely available to nonsubscribers on JCP’s Web site, Psychiatrist.com. The charge for this service is $2,500 and is payable by check or credit card. Authors are provided this option at the time of acceptance.
Your article reaches about 36,000 readers of the print journal, but the JCP Web site attracts over 250,000 visitors each month, most of whom are nonsubscribers who must pay a fee to read an entire article online. The option of financial sponsorship allows you to provide each Web visitor unrestricted access to your HTML article, thereby increasing its potential audience nearly 6-fold. To further expand your article’s visibility, an e-mail announcement of its Free status is also sent to over 40,000 JCP E-Lert requestors.
Submission of payment signifies your agreement to the Terms and Conditions for copyrighted work.
Single copies of articles or back issues, as well as larger quantities of high-quality photocopies or reprints, can be purchased from email@example.com. At the time of publication, all authors are sent notification when their manuscript publishes. Corresponding authors receive a complimentary PDF with instructions on how the PDF may and may not be used. Learn more about reprints, eprints, and permissions at this links: Reprints and Permissions. (See also Copyright Policy and Terms and Conditions.)
Physician’s Postgraduate Press, Inc., owns the copyrights for the material published in its publications, The Journal of Clinical Psychiatry and The Primary Care Companion for CNS Disorders, and their associated Web sites. The information as it is presented in all forms is the property of the Company. See Reprints and Permissions for how to acquire permission to use copyrighted material.
All materials published by Physicians Postgraduate Press, Inc., are the property of Physicians Postgraduate Press, Inc., unless otherwise stated, and are subject to all laws pertaining to copyrighted work.
Retention of copyright by Physicians Postgraduate Press, Inc., means the work may not be reproduced or transmitted in any form or by any means, including electronic, photocopying, or otherwise; distributed in any form or by any means; publicly displayed in any form including but not limited to Internet, Extranet, PowerPoint, or posters; and used for commercial, promotional, or marketing purposes, which include sale, resale, transfer, loan, license, or other forms of commercial exploitation. (See also Copyright Policy.)
All manuscripts, including letters to the editor, must be accompanied by an electronic cover letter. Manuscripts are reviewed with the understanding that they represent original material, have never been published before, are not under consideration for publication elsewhere, and have been approved by each author. Prior publication constitutes any form of publication other than an abstract or clinical trial registration and includes invited articles, proceedings, symposia, and book chapters. Authors should fully inform the editor in the cover letter if the submitted manuscript contains data or clinical observations that have been published or submitted for publication elsewhere, supply copies of such material, and explain the differences between the works.
Manuscripts should have margins of at least 1 in and be double-spaced throughout, including title page, abstract, text, references, tables, and legends for figures. Number pages consecutively in the upper right-hand corner, beginning with the title page. Each section should begin on a separate page, and the sections should be arranged in the following order: (1) title page, (2) abstract and key words, (3) text, and (4) references. Tables and figures should be submitted as separate file(s) from the manuscript.
The title of the article should be concise but informative and should convey the basic design of the study.
For each author, provide first name, middle initial, and last name along with highest academic degree(s) and departmental and institutional affiliation, including city/state/country location.
At the bottom of the title page, list the following:
If you are submitting an article, you are required to include a structured abstract of about 250 words or less. The abstract must reflect the text or graphics; that is, no information should be included in the abstract that cannot be drawn from the text or graphics.
Objective: State the question addressed in the study.
Method: Describe the basic study design. State the setting (eg, primary care, referral center). Explain selection of study subjects and state the system of diagnostic criteria used. Describe any interventions and include their duration and method of administration. Indicate the main outcome measure(s). Specify the dates in which data were collected (month/year to month/year).
Results: Include the key findings. Give specific data and their statistical significance, if possible (include P value if findings were significant). Subset Ns should accompany percentages if the total N is < 100.
Conclusion: Summarize the conclusions.
Clinical Trials Registration: If the article reports a clinical trial, give the trial registry name, URL, and registration number.
Objective: State the primary objective of the article.
Data Sources: Describe the data sources that were searched, including dates, keywords, and constraints (eg, language limits).
Study Selection: Identify the number of studies reviewed and the criteria used for their selection.
Data Extraction: Summarize guidelines used for abstracting data and how they were applied.
Results: State the main results of the review and the methods used to obtain these results.
Conclusions: Summarize the conclusions.
Data Sources: Describe the data sources that were searched, including dates, keywords, and constraints (eg, language limits). If the list of search terms is complicated and somewhat lengthy, a summary of terms can be used in the abstract.
Study Selection: Identify the number of studies retrieved and ultimately reviewed and the criteria used for their selection. By reading the abstract, the reader should be able to follow the progression of the process.
Data Extraction: Summarize guidelines used for abstracting data for the meta-analysis and how they were applied. The case-control study information under Method should be incorporated here.
Objective: State the issue, purpose, and intended audience.
Participants: Describe how people were chosen to be participants, state the number of participants, and describe their areas of expertise. State whether meetings were open or closed.
Evidence: Describe what data sources were used and explain their selection, abstraction, and the method of their synthesis. If a formal literature review was conducted, state who wrote it and whether it was reviewed. Describe any use of unpublished data. Explain the influence of expert opinion and comments from the participants.
Consensus Process: Describe the basis for conclusions. State how consensus was achieved. Describe the writing of the consensus statement, including who wrote it, whether it was drafted before or after the group expressed its opinions, and when it was written. Explain who reviewed the statement and how revision suggestions were utilized.
Conclusions: Summarize the consensus statement, and include any important minority views.
Further details on writing informative structured abstracts can be obtained from the following:
Letters must include a descriptive title, but they should not have an abstract. Most letters to the editor either report cases or small studies or comment on a recent journal article. Letters to the Editor and case reports should not exceed 600 words and 1 table or figure.
Case reports should describe novel, well-documented findings that will be of use to the practitioner.
For case reports and small studies, ensure that the chronology of events is clear, and specify the month/year in which events occurred. Specify diagnostic criteria used for any diagnoses mentioned, and provide references for scales/assessment tools used. If a search of the literature was conducted for related case reports, specify the data sources, keywords, and any date/language limitations used in the search.
Letters reporting small studies typically include (1) a brief introductory paragraph, (2) sections titled "Method" and "Results" (labeled with capitalized headings), and (3) a conclusions/discussion section.
Letters reporting cases typically consist of (1) a brief introductory paragraph, (2) description of the cases, and (3) a discussion section. For letters reporting multiple cases, the types of clinical and demographic details given (eg, race, gender, occupation, marital status, medications, follow-up) should be consistent among the cases. It is not necessary to include all of these details in case reports, but if a particular characteristic, eg, occupation, is reported for one case, it should be reported for all of the cases.
For letters commenting on a Journal article, include a numbered reference to the article discussed. Be concise, and support your assertions with references as applicable. Also, please note that the authors of the original article will be given the opportunity to reply to letters commenting on their article. Letters that pertain to recent articles in the Journal should not exceed 500 words.
The text of observational and experimental articles is usually--but not necessarily--divided into sections with the headings Introduction, Method, Results, and Discussion. Lengthy articles may need subheadings within some sections to clarify their content. Manuscripts should have a maximum length of 3,000 words (excluding abstract, tables, figures, and references).
State the purpose of the article. Summarize the rationale for the study or observation. Give only strictly pertinent references, and do not review the subject extensively. Do not include data or conclusions from the work being reported.
Describe your selection of the observational or experimental subjects (including controls) clearly, including eligibility. Identify the methods, apparatus (manufacturer's name and city/state/country location in parentheses), and procedures in sufficient detail to allow other workers to reproduce the results. Give references to established methods, including statistical methods (see below). Include references for all assessment tools, including scales, used in the study. Describe new or modified methods, give reasons for using them, and evaluate their limitations. Identify precisely all drugs and chemicals used, including generic name(s), dose(s), and route(s) of administration. Specify the dates in which data were collected (month/year to month/year).
Present your results in logical sequence. Do not repeat in the text all the data in the tables or figures; emphasize or summarize only important observations. Subset Ns should accompany percentages if the total N is < 100. For original research, results should not be shown as not significant or NS. Actual P values are important for future meta-analyses research. Please include actual P values, and preferably confidence intervals or limits, when reporting nonsignificant results.
Emphasize the new and important aspects of the study and the conclusions that follow from them. Do not repeat in detail material given in the Introduction or the Results section. Present in the Discussion section the implications of the findings and their limitations, including implications for future research. Relate the observations to other relevant studies. Link the conclusions with the goals of the study but avoid unqualified statements and conclusions not completely supported by your data.
When preparing review articles and meta-analyses, describe the methods used in performing the literature review. This description includes listing the data sources searched (for example, MEDLINE) and the dates, keywords, and constraints (for example, language limits) used in the search; the criteria used to select the included studies; and the guidelines used for abstracting and synthesizing the data. Word limit for review articles and meta-analyses should not exceed 5,000 words of text.
In meta-analyses, several basic content areas should be addressed: study design, combinability, control of bias, statistical analysis, sensitivity analysis, and problems of applicability.
Please refer to the information on Abstracts for a more detailed framework of the necessary elements for review articles and meta-analyses.
Consensus statements should identify the participants and their areas of expertise, as well as the source of funding or sponsor. Describe the data sources used and explain their selection, abstraction, and the method of their synthesis. A description of the process used to reach consensus should be included. Explain how conclusions were reached.
Please refer to the information on Abstracts for a more detailed framework of the necessary elements for consensus statements. Word limit for consensus statements should not exceed 5,000 words.
The reference list should include only references to information that is retrievable. Authors are responsible for verifying the accuracy and completeness of the references against the original publications or presentations. Reference lists are limited to 75 references.
Reference 28 is the last reference cited in text before the Table 1 callout, which has references not yet cited in text, starting with reference 29 and going through 77. Text in the Discussion picks up with the next new reference, 78.
. . . Metabolite ratios including glutamate have been found to change with age.27,28 Table 1 shows the characteristics of each study, compares glutamatergic metabolites . . .
“. . . while 1 previous 6-month study30 reported no increase in relapse following an approximately 25% dose reduction of olanzapine, a 1-year study31 did demonstrate an increase in relapse. . . ”
“. . . using the data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies.18,19”
“. . . a higher D2 receptor occupancy with atypical antipsychotics has been associated at least partly with cognitive impairment,3 negative subjective experience,4 and hyperprolactinemia.5”
Format if author name(s) are used:
1 author: “Smith2 states that...”
2 authors: “Smith and Jones2 state that...”
3 or more authors: “Smith et al2 state that...” or “Smith and colleagues2 state that...”
The journal follows the AMA Manual of Style, 10th edition. Abbreviations of journal names must conform to Index Medicus style.
Unpublished material includes personal communications and unpublished data such as data on file and manuscripts in preparation, submitted but not yet accepted, or in press.
Ways to include these citations and the requirements for each specific type of unpublished material:
To include a personal communication from each person you identify as a source of information:
In the manuscript, authors must
In the submission system:
Similar findings have been noted in other studies (see references 10–12 and J. M. Doe, PhD, written communication, November 2014).
Similar findings were noted in a conversation with the manufacturer (R. Smith, MD, August 2013).
To include unpublished data from each person you identify as a source of information:
In the manuscript, authors must
In this example, written permission is needed from all 3 persons cited:
Similar findings have been noted in other studies10–12 and by J. M. Doe, PhD; R. Smith, MD; and T. H. Jones, MD, PhD (unpublished data, 2014).
In this example, X.P.Q. is a bylined author and separate written permission is not needed. However, some bylined authors may want to give credit to colleagues, in which case up to 2 additional researchers may be included in a list of 3 researchers, if warranted, eg, J. M. Doe, PhD; X.P.Q.; and T. H. Jones, MD, PhD (unpublished data, 2014); written permission is then needed from the other 2 researchers, in this case, Doe and Jones:
Another study (X.P.Q., unpublished data, 2013) has confirmed the findings of Williams et al.7
When performing a meta-analysis, you may sometimes need to contact the author of an article you’re citing for information that was not published, eg, to learn the disposition of a subject or whether certain data were collected but not reported in the original study. If you contact these authors and further information is provided:
Twenty of the 25 patients in Doe et al completed grade 12 (J. M. Doe, PhD, unpublished data, 2014).
According to Smith et al, none of the patients experienced nausea (T. Smith, MD, verbal communication, January 22, 2015).
Data on file from a pharmaceutical company are considered unpublished data.
In the manuscript, authors must
When citing an unpublished manuscript, consider that the status of the cited manuscript may change substantially from the time when your manuscript is submitted/accepted until the time it is published. Before citing unpublished data, consider whether doing so could jeopardize publication of the manuscript still in review, ie, whether publication of your manuscript could potentially “scoop” the data presented in the one still under review. If it could, then you should not publish outcomes reported in that manuscript, and the relevant information should be removed from your article.
When citing data from a manuscript that has been submitted but that has not yet been accepted, you must consider whether publication of the data could jeopardize publication of the manuscript still under review, ie, whether it could potentially “scoop” that manuscript’s data presented. If it could, then you should not publish outcomes reported in that manuscript, and the relevant information should be removed from your article.
If you still wish to cite a submitted—but not yet accepted—manuscript, the citation must be placed in text and not in the numbered bibliographic references. It is labeled as “unpublished data,” and the same rules apply as for unpublished data:
Manuscripts accepted for publication are considered “in press” and should be listed in the bibliographic reference list and numbered consecutively with other citations in text.
If you’ve cited a submitted manuscript that is later accepted (becomes “in press”) during the review process of your manuscript, Journal staff should be notified, and a decision will be made whether to add the now “In press” manuscript to the references and renumber the list or simply footnote the full reference. The style would resemble the following:
Doe JM, Smith R, Jones TH, et al. Effect of drug A on depression severity. J Clin Psychiatry. In press.
If you want to cite one of your manuscripts that is still in development, and it has data that have not yet been submitted to a journal, it can be cited parenthetically in text as "manuscript in preparation"; however, you need to be aware that citing results in this current manuscript could constitute previous publication and may jeopardize future acceptance of the in-preparation manuscript. Authors will need to provide the same information as for unpublished data.
Computer-generated figures should be submitted as separate files (minimum 300 dpi). Please provide . . .
Tables and figures should not duplicate text or one another and must be self-explanatory. Tables should be numbered consecutively in the order of their first citation in the text, as should figures. Acknowledge the original source of a previously published or adapted table or figure and submit written permission from the copyright holder to reproduce the material.
Footnotes. 3 types:
Tables. Identify each table by a brief descriptive title. Give each column a short heading. When percentages are presented, the appropriate numbers must also be given. Do not use internal horizontal and vertical rules. Place explanatory matter in footnotes, not in the headings or title. Units of measurement should be specified. Definitions of symbols appearing in tables should be listed at the end of the footnotes, with the expansions of abbreviations.
Figures. Two-dimensional graphs should not be represented in 3 dimensions. Figures are usually reduced to a width of 19.5 picas (3.25 in, 8.2 cm). Definitions of symbols appearing in the figure should be presented in a key (or legend) within the figure, rather than in the title or footnotes. The key should appear within or above the figure but should not widen the figure.
References Within Graphics. Ensure references embedded within a graphic are numbered consecutively with the text, from where graphic’s callout is first cited. See Citing References in Text and Graphics.
The journal accepts submissions of supplementary material, which will be posted online in support of a printed article. Appendixes will be published online only as supplementary material. Appendixes should be labeled as eAppendix 1. For all other supplementary material, please label supplemental graphics, in text and on the graphic itself, as "Supplementary e[Table, Figure, etc.] 1, 2, etc. Supplementary material will not be edited and should be uploaded as a single PDF file with the file type "Supplementary material" selected. All supplementary material is subject to a posting fee. Contact JClinPsych@psychiatrist.com for more information.
All manuscripts submitted for Special Section consideration (as indicated by authors at the time of electronic submission) will undergo the Journal’s usual editorial evaluation and peer review. Authors are invited to submit both high-quality research manuscripts and scholarly reviews. Only full-length articles are eligible for inclusion in special sections. Letters to the Editor will not be considered for these sections.
The objective of the Early Career Psychiatrists section is to encourage the academic development of early career psychiatrists. Manuscripts selected for this section will be those deemed through the review process to represent excellent work from the next generation of researchers in psychiatry.
Eligibility criteria for first authors:
The objective of the Focus on Addiction section is to promote scientifically rigorous research on substance-related and addictive disorders, including etiology, epidemiology, diagnosis, prevention, and treatment. The section’s scope embraces comorbidity of addiction with other psychiatric and medical disorders. Relevant multidisciplinary and translational approaches encompass genetics, molecular biology, cognitive-behavioral science, neuroscience, brain stimulation and imaging, pharmacology, and translational medicine. Articles published in the section will display clinical excellence and support JCP’s commitment to reduce the overall burden of psychiatric illness.
To encourage scientific studies relating to the mental health of older adults, JCP is calling for submissions to the Focus on Geriatric Psychiatry, edited by Gary W. Small, MD, and Helen Lavretsky, MD. Topics of interest include late-life depression, memory disorders including Alzheimer’s disease, dementia, grief, anxiety, resilience, and cognition. Manuscripts may address any biological, psychosocial, economic, or health services aspect of mental health in older adults, including preventive and lifestyle-related factors, care in nursing home settings, and end-of-life care. We invite high-quality research focusing on various treatment modalities, including pharmacologic treatment, psychotherapy, and complementary therapies. All submitted manuscripts will undergo the Journal’s usual editorial evaluation and peer review.
The objective of the Focus on Childhood and Adolescent Mental Health section is to encourage scientific studies regarding the mental health of children and adolescents, promote excellent clinical care of children and adolescents with psychiatric disorders, and help keep the psychiatric community informed about the latest research developments. In addition to manuscripts covering studies of the phenomenology of childhood and adolescent psychiatric disorders and clinical trials of treatments for childhood and adolescent psychiatric disorders and associated symptoms, authors are encouraged to submit manuscripts regarding the use of genomic and brain imaging studies related to childhood and adolescent mental health. Disorders include pediatric mood, anxiety, and psychotic disorders as well as oppositional defiant and conduct disorders, attention-deficit/hyperactivity disorder, pervasive developmental disorders, tic disorders, mental retardation, other developmental disorders, and any other disorder that may present during childhood or adolescence. Other topics include any biological, psychosocial, economic, or health services aspect of childhood and adolescent mental health. We also invite manuscripts related to the scientific understanding, differential diagnosis, early detection and monitoring, treatment, and prevention of psychiatric disorders in children and adolescents.
The objective of the Focus on Suicide section is to promote scientific research into the causes and prevention of suicide. Identification of risk and protective factors related to suicidal behavior, diagnosis of at-risk persons, evidence-based intervention research, treatment and practice strategies, interdisciplinary approaches, brain imaging and genomic studies are all of interest. In selecting articles on suicide, JCP aligns its goals with those set forth in February 2014 by the National Alliance for Suicide Prevention’s Research Prioritization Task Force in A Prioritized Research Agenda for Suicide Prevention. Authors are invited to submit high-quality research and scholarly reviews on all aspects of suicide that will contribute to the overall decrease in the global burden of suicide.
The objective of the Focus on Women’s Mental Health section is to recognize and address the need for gender-based research. Authors are invited to submit well-designed, well-conducted studies of epidemiologic, biological, psychosocial, economic, and health services aspects of women’s mental health issues. Topics of interest include all aspects of mental health issues pertinent to the female reproductive lifespan, disorders that disproportionately affect women, and inquiries into how gender impacts the course and treatment of disorders that affect the sexes equally.
The objective of the Social Media and Mental Health section is to foster inquiry into the evolving relationship between psychiatry and social media. Authors are invited to submit well-designed original research and scholarly reviews related to social media technologies, including social networking websites, blogs, and Internet forums. An emerging field of study that is of particular interest is the use of “big data” mined from social media data to reveal patterns and predict the spread of disorders and mental health¬–related phenomena. Another area of focus is the impact of individuals’ social media use on their mental health (effects on mood, social media addiction, and other topics). Authors are also encouraged to submit manuscripts that investigate promising ways in which social media can be leveraged by mental health professionals to provide interventions, disseminate public health information, or communicate with patients.
Physicians Postgraduate Press, Inc.
Lifelong Learning for Clinicians
MedFair.com US Patent No. 6847940